March 19, 2021
Three Reckitt Benckiser Group PLC shareholders launched a derivative complaint Thursday accusing the pharmaceutical company's executives of allowing the criminal and civil misconduct leading to a $1.4 billion settlement to resolve the government's allegations over the company's marketing of opioid addiction treatment Suboxone.